The platform enables direct, unbiased genome-wide identification and quantification of the exact position of double strand DNA breaks in edited cells.
Prime Medicine, Inc. faces risks in the gene editing sector despite positive developments, caution advised for retail investors. Click for my PRME stock update.
International collaborations, refined gene-editing protocols, and targeted immunologic maneuvers keep the cancer gene therapy ...
Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback